Hepatitis C, other infectious diseases and drug-related harms

In programme
11 sessions 49 presentations View the programme

About

This track is co-produced by the International Network on Health and Hepatitis in Substance Users (INHSU).

  • Reducing drug-related harms: Hepatitis C, other infectious diseases, soft-tissue infections and overdose.
  • Evidence and global examples of service delivery and interventions that improve the health of people who use drugs.

Sessions

Wednesday, 23 November

10:50

Drug treatment

10:50 to 12:20
Knowledge market 3 (K3)
Oral presentation session
13:20

Hepatitis C epidemiology and prevention

13:20 to 14:50
Knowledge market 3 (K3)
Oral presentation session
15:00

Injecting-related infections and drug surveillance

15:00 to 16:30
Knowledge market 3 (K3)
Oral presentation session
16:50

Hepatitis C prevention and treatment among people who inject drugs: Global progress and future requirements

16:50 to 18:20
Knowledge market 3 (K3)
Structured session

Improving the health of people who use drugs

16:50 to 18:20
Networking zone 4 (N4)
Short communication session

Thursday, 24 November

10:50

How can we improve global coverage of interventions to reduce drug-related harms?

10:50 to 12:20
Main stage
Structured session
13:20

Hepatitis C testing and treatment

13:20 to 14:50
Knowledge market 3 (K3)
Oral presentation session
15:00

Models to improve the health of people who inject drugs

15:00 to 16:30
Knowledge market 3 (K3)
Oral presentation session

Prevention, testing and treatment of Hepatitis C and other infections

15:00 to 16:30
Networking zone 4 (N4)
Short communication session

Friday, 25 November

10:50

Mortality among people who use drugs

10:50 to 12:20
Knowledge market 3 (K3)
Oral presentation session
13:20

Overdose prevention

13:20 to 14:50
Knowledge market 3 (K3)
Oral presentation session

Presentations

Wednesday, 23 November

10:50
Oral presentation

A qualitative exploration of patient’s experience of mobile telephone-delivered Contingency Management (mCM) to promote adherence to supervised methadone in UK pharmacies

10:50 to 12:20
Knowledge market 3 (K3)
Carol-Ann Getty
Oral presentation

I don’t chase drugs anymore and I’m not dead': The Impact of Safer Opioid Supply Programs in Ontario Canada on Client’s Health and Drug Use

10:50 to 12:20
Knowledge market 3 (K3)
Rose Schmidt
Oral presentation

Delivering telemedicine to vulnerable people with opioid use disorder: Outcomes of a program co-constructed and implemented with a community-based harm reduction service in Montreal, Canada

10:50 to 12:20
Knowledge market 3 (K3)
Stine Hoj
Oral presentation

Access to their own drugs': Navigating the drawbacks and benefits of injectable hydromorphone and diacetylmorphine treatment in Vancouver, BC

10:50 to 12:20
Knowledge market 3 (K3)
Samara Mayer
13:20
Oral presentation

Assessing the impact of COVID-19 and associated control measures on interventions to prevent drug-related harm among people who inject drugs in Scotland

13:20 to 14:50
Knowledge market 3 (K3)
Kirsten Trayner
Oral presentation

The Contribution of Unstable Housing to HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs Globally, Regionally, and at Country Level: A Modelling Study

13:20 to 14:50
Knowledge market 3 (K3)
Jack Stone
Oral presentation

The effectiveness of low dead space syringes for reducing the risk of hepatitis C virus acquisition among people who inject drugs - findings from a national survey in UK

13:20 to 14:50
Knowledge market 3 (K3)
Peter Vickerman
Oral presentation

Global incidence of hepatitis C virus (HCV) and HIV infection among people who inject drugs: A systematic review and meta-analysis

13:20 to 14:50
Knowledge market 3 (K3)
Adelina Artenie
15:00
Oral presentation

Fear of inpatient opioid withdrawal: Addressing a modifiable barrier to health-care access for people who use illicit opioids.

15:00 to 16:30
Knowledge market 3 (K3)
Magdalena Harris
Oral presentation

Analysis of drugs in used syringes from sentinel European cities, 2020

15:00 to 16:30
Knowledge market 3 (K3)
Thomas Seyler
Oral presentation

The impact of opioid agonist treatment on hospitalisations for injecting-related diseases: a retrospective data linkage study

15:00 to 16:30
Knowledge market 3 (K3)
Samantha Colledge-Frisby
Oral presentation

Association of opioid agonist treatment with mortality or rehospitalization following injection drug use-associated bacterial and fungal infections: linkage cohort study

15:00 to 16:30
Knowledge market 3 (K3)
Thomas Brothers
16:50
Short communication

Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double dummy, randomised, controlled trial

16:50 to 18:20
Networking zone 4 (N4)
Arne Skulberg
Short communication

Monitoring overall mortality among people who are using drugs in Europe: A good practice example for international cooperation via the REITOX network

16:50 to 18:20
Networking zone 4 (N4)
Tanja Schwarz
Short communication

Developing an Intervention to Manage Benzodiazepine Dependence and High-Risk Use in the Context of Escalating Drug Related Deaths: A feasibility study

16:50 to 18:20
Networking zone 4 (N4)
Catriona Matheson
Short communication

Housing-based syringe services programs to improve access to safe injecting supplies for people who inject drugs in Vancouver, Canada: A spatially-oriented qualitative study

16:50 to 18:20
Networking zone 4 (N4)
Koharu Loulou Chayama
Short communication

Registration for opioid agonist treatment in Ireland from 1999 to 2019: positive findings in younger individuals.

16:50 to 18:20
Networking zone 4 (N4)
Peter McCarron
Short communication

The role of a medically supervised injecting room in improving access to health and social services.

16:50 to 18:20
Networking zone 4 (N4)
Nico Clark
Short communication

Barriers and facilitators for use of oral healthcare services among people with substance use disorders: A qualitative study in Norway

16:50 to 18:20
Networking zone 4 (N4)
Siv-Elin Carlsen
Oral presentation

1. Interventions to enhance prevention of hepatitis C and HIV infection

16:50 to 18:20
Knowledge market 3 (K3)
Julie Bruneau
Oral presentation

2. Treatment as prevention for hepatitis C infection: A key piece to the elimination puzzle

16:50 to 18:20
Knowledge market 3 (K3)
Matthew Hickman
Oral presentation

3. We have reached single-diagnosis and treatment for hepatitis C infection: What next?

16:50 to 18:20
Knowledge market 3 (K3)
Jason Grebely
Oral presentation

4. Community-led initiatives to enhance prevention and treatment for hepatitis C

16:50 to 18:20
Knowledge market 3 (K3)
Judy Chang

Thursday, 24 November

10:50
Oral presentation

1. Global epidemiology of injecting drug use, HIV/HCV among people who inject drugs, and coverage of interventions to reduce drug-related harms

10:50 to 12:20
Main stage
Louisa Degenhardt
Oral presentation

2. Successful models for implementation of harm reduction programmes

10:50 to 12:20
Main stage
Monica Ciupagea
Oral presentation

3. How can we improve data and mobilise funding for harm reduction support globally?

10:50 to 12:20
Main stage
Keith Sabin
Oral presentation

4. Community advocacy and community-led monitoring to improve coverage and quality of services to reduce drug-related harms

10:50 to 12:20
Main stage
Judy Chang
13:20
Oral presentation

Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study

13:20 to 14:50
Knowledge market 3 (K3)
Anna Conway
Oral presentation

Non-uptake of treatment for hepatitis C in the antiviral era: A qualitative analysis

13:20 to 14:50
Knowledge market 3 (K3)
Suzanne Fraser
Oral presentation

A novel hepatitis C intervention in Denmark to test and treat people who inject drugs

13:20 to 14:50
Knowledge market 3 (K3)
Jonas Demant
15:00
Oral presentation

The social, material and temporal effects of extended-release buprenorphine depot treatment for opioid dependence: an Australian qualitative study

15:00 to 16:30
Knowledge market 3 (K3)
Kari Lancaster
Short communication

Real-world hepatitis C treatment outcomes among people who inject drugs at the Stockholm needle exchange program, Sweden

15:00 to 16:30
Networking zone 4 (N4)
Martin Kåberg
Short communication

Educations for safer injection in the Mobile Drug Consumption Room in Lisbon

15:00 to 16:30
Networking zone 4 (N4)
Ângela Leite
Short communication

Real time surveillance on the impact of restrictions on harm reduction services to improve responsiveness and reduce harms in unprecedented times

15:00 to 16:30
Networking zone 4 (N4)
Josie Smith
Short communication

Harm reduction services in the Netherlands: recent developments and challenges.

15:00 to 16:30
Networking zone 4 (N4)
Nadine G.M. van Gelder
Oral presentation

Serious non-fatal and fatal opioid overdose events in a cohort of hospital patients seen by an addiction consultation service: Secondary analysis of the NavSTAR trial.

15:00 to 16:30
Knowledge market 3 (K3)
Jan Gryczynski
Oral presentation

Screening, diagnosis and treatment of infectious diseases with at-risk populations: 20 years of data from a harm reduction program managed by Ares do Pinhal in Lisbon

15:00 to 16:30
Knowledge market 3 (K3)
Filipa Barata
Oral presentation

Peer-led community based infectious disease integrated testing and linkage to care in inclusion health populations in London, UK

15:00 to 16:30
Knowledge market 3 (K3)
Julian Surey
Short communication

Transactional sex as a pathway for rising sexually transmitted infections amidst the opioid epidemic in the United States

15:00 to 16:30
Networking zone 4 (N4)
Mance Buttram
Short communication

Hepatitis C reinfection following successful direct-acting antiviral therapy among patients attending a multidisciplinary treatment centre for people who use drugs in Zurich, Switzerland

15:00 to 16:30
Networking zone 4 (N4)
Claudia Bernardini
Short communication

Individual and structural factors associated with recent hepatitis C testing in people who inject drugs: gender-based analyses of the Cosinus Cohort

15:00 to 16:30
Networking zone 4 (N4)
Ilhame Anwar

Friday, 25 November

10:50
Oral presentation

Increased risk of non-fatal overdose associated with NPS-type [‘street’] benzodiazepine use in Scotland, UK

10:50 to 12:20
Knowledge market 3 (K3)
Andrew McAuley
Oral presentation

Variations in the protective association between opioid agonist therapy and opioid overdose death by age and chronic disease status: findings from the OATS retrospective linked data study, NSW, Australia, 2001-2018.

10:50 to 12:20
Knowledge market 3 (K3)
Sarah Larney
Oral presentation

Temporal trend in the survival of injecting and non-injecting heroin-dependent patients admitted to treatment in Barcelona, Spain: a 30-year cohort study.

10:50 to 12:20
Knowledge market 3 (K3)
Anna Hernández-Rubio
Oral presentation

The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018.

10:50 to 12:20
Knowledge market 3 (K3)
Nicola Jones
13:20
Oral presentation

Binge drug injection among people who inject drugs in Montreal: characterizing the substances and social contexts involved to inform overdose prevention efforts

13:20 to 14:50
Knowledge market 3 (K3)
Nanor Minoyan
Oral presentation

Seven years with take-home naloxone for overdose prevention in Norway: who are the first responders and how do they perform?

13:20 to 14:50
Knowledge market 3 (K3)
Øystein Bruun Ericson
Oral presentation

Post-Overdose Outreach Programs in Massachusetts: Lessons Learned, Impact and Best Practice Guidance

13:20 to 14:50
Knowledge market 3 (K3)
Alexander Walley
Oral presentation

The impact of the WHO/UNODC S-O-S training package on opioid overdose response knowledge and attitudes

13:20 to 14:50
Knowledge market 3 (K3)
Paul Dietze
View all tracks